Clinical Trial Update: Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 neoadjuvant trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) versus TC (docetaxel and cyclophosphamide) in triple-negative and HER2-positi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED